Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice

Experimental Neurology

Volumn 280, Issue , 2016, Pages 13-23

  Guo, Chuang ^a   Hao, Li Juan ^a   Yang, Zhao Hui ^a   Chai, Rui ^a   Zhang, Shuai ^a   Gu, Yu ^a   Gao, Hui Ling ^a   Zhong, Man Li ^a   Wang, Tao ^a   Li, Jia Yi ^a   Wang, Zhan You ^a  

^a NORTHEASTERN UNIVERSITY   (China)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Deferoxamine; Hypoxia inducible factor; Iron; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DEFEROXAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NEUROMODULIN; PROTEIN BAX; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TRANSFERRIN RECEPTOR; VASCULOTROPIN; HIF1A PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; STAINING; SUBSTANTIA NIGRA; TREATMENT DURATION; UPREGULATION; ANIMAL; APOPTOSIS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; METABOLISM; MPTP POISONING; NEUROBLASTOMA; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CELL LINE, TUMOR; DEFEROXAMINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EXPLORATORY BEHAVIOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MPTP POISONING; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 84962295938     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.03.016     Document Type: Article

References (70)

1. +/MPTP-lesioned dopaminergic neurons. PLoS One 2015, 10.
2. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56:1441-1444.
3. Ben-Shachar D., Eshel G., Riederer P., Youdim M.B. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 1992, (32 Suppl.):S105-S110.
4. Bianchi L., Tacchini L., Cairo G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res. 1999, 27:4223-4227.
5. Bush A.I., Tanzi R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008, 5:421-432.
6. Chen S., Wang Y., Ruan W., Wang X., Pan C. Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. Oncol. Lett. 2014, 8:2333-2339.
7. Comerford K.M., Cummins E.P., Taylor C.T. C-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004, 64:9057-9061.
8. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 1995, 65:717-724.
9. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
10. Cuajungco M.P., Faget K.Y., Huang X., Tanzi R.E., Bush A.I. Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 920:292-304.
11. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
12. Dexter D.T., Statton S.A., Whitmore C., Freinbichler W., Weinberger P., Tipton K.F., Della Corte L., Ward R.J., Crichton R.R. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural Transm. 2011, 118:223-231.
13. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 2:1219-1220.
14. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
15. Febbraro F., Andersen K.J., Sanchez-Guajardo V., Tentillier N., Romero-Ramos M. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model. Exp. Neurol. 2013, 247:45-58.
16. Fernandez-Gonzalez A., Perez-Otano I., Morgan J.I. MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur. J. Neurosci. 2000, 12:1573-1583.
17. Fine J.M., Baillargeon A.M., Renner D.B., Hoerster N.S., Tokarev J., Colton S., Pelleg A., Andrews A., Sparley K.A., Krogh K.M., Frey W.H., Hanson L.R. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp. Brain Res. 2012, 219:381-390.
18. Fine J.M., Forsberg A.C., Renner D.B., Faltesek K.A., Mohan K.G., Wong J.C., Arneson L.C., Crow J.M., Frey W.H., Hanson L.R. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of parkinsons disease. Brain Res. 2014, 1574:96-104.
19. Gao H.L., Li C., Nabeka H., Shimokawa T., Saito S., Wang Z.Y., Cao Y.M., Matsuda S. Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin. Neuroscience 2013, 236:373-393.
20. +). J. Neural Transm. (Vienna) 2011, 118:421-431.
21. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
22. Guo C., Wang P., Zhong M.L., Wang T., Huang X.S., Li J.Y., Wang Z.Y. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 2013, 62:165-172.
23. Guo C., Wang T., Zheng W., Shan Z.Y., Teng W.P., Wang Z.Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:562-575.
24. Guo C., Zhang Y.X., Wang T., Zhong M.L., Yang Z.H., Hao L.J., Chai R., Zhang S. Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1alpha pathway on the brain of APP/PS1 transgenic mice. Front. Aging Neurosci. 2015, 7:104.
25. Gupta S.K., Mishra R., Kusum S., Spedding M., Meiri K.F., Gressens P., Mani S. GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986. Cell Death Differ. 2009, 16:624-637.
26. Haleagrahara N., Siew C.J., Ponnusamy K. Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. J. Toxicol. Sci. 2013, 38:25-33.
27. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35:1147-1150.
28. Hanson L.R., Roeytenberg A., Martinez P.M., Coppes V.G., Sweet D.C., Rao R.J., Marti D.L., Hoekman J.D., Matthews R.B., Frey W.H., Panter S.S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 2009, 330:679-686.
29. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., Agid Y., Hirsch E.C. Is bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. J. Neurochem. 2001, 76:1785-1793.
30. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51:S2-S9.
31. Kalivendi S.V., Cunningham S., Kotamraju S., Joseph J., Hillard C.J., Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 2004, 279:15240-15247.
32. +)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem. J. 2003, 371:151-164.
33. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
34. Kupershmidt L., Weinreb O., Amit T., Mandel S., Bar-Am O., Youdim M.B. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 2011, 189:345-358.
35. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
36. Lim J., Kim H.I., Bang Y., Seol W., Choi H.S., Choi H.J. Hypoxia-inducible factor-1alpha upregulates tyrosine hydroxylase and dopamine transporter by nuclear receptor ERRgamma in SH-SY5Y cells. Neuroreport 2015, 26:380-386.
37. Lin S.M., Wang S.W., Ho S.C., Tang Y.L. Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. Nutrition 2010, 26:1195-1200.
38. Lv H., Liu J., Wang L., Zhang H., Yu S., Li Z., Jiang F., Niu Y., Yuan J., Cui X., Wang W. Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease. Cell Biochem. Biophys. 2014, 70:1433-1438.
39. Mounsey R.B., Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int. J. Cell Biol. 2012, 2012:983245.
40. Norris M.L., Millhorn D.E. Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. J. Biol. Chem. 1995, 270:23774-23779.
41. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
42. Perron N.R., Hodges J.N., Jenkins M., Brumaghim J.L. Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg. Chem. 2008, 47:6153-6161.
43. Ravanti L., Toriseva M., Penttinen R., Crombleholme T., Foschi M., Han J., Kahari V.M. Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase. FASEB J. 2001, 15:1098-1100.
44. Rekart J.L., Meiri K., Routtenberg A. Hippocampal-dependent memory is impaired in heterozygous GAP-43 knockout mice. Hippocampus 2005, 15:1-7.
45. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 2008, 32:183-195.
46. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 1999, 274:32631-32637.
47. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci. 2004, 1012:326-341.
48. Rothblat D.S., Schroeder J.A., Schneider J.S. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental parkinsonism. J. Neurosci. Res. 2001, 65:254-266.
49. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nunez M.T., Garrick M.D., Raisman-Vozari R., Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18578-18583.
50. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P., Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 2002, 24:143-153.
51. Saporito M.S., Thomas B.A., Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 2000, 75:1200-1208.
52. Schnell P.O., Ignacak M.L., Bauer A.L., Striet J.B., Paulding W.R., Czyzyk-Krzeska M.F. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J. Neurochem. 2003, 85:483-491.
53. Serra P.A., Sciola L., Delogu M.R., Spano A., Monaco G., Miele E., Rocchitta G., Miele M., Migheli R., Desole M.S. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J. Biol. Chem. 2002, 277:34451-34461.
54. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46:254-263.
55. Shi Z.H., Nie G., Duan X.L., Rouault T., Wu W.S., Ning B., Zhang N., Chang Y.Z., Zhao B.L. Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. Antioxid. Redox Signal. 2010, 13:783-796.
56. Siddiq A., Aminova L.R., Ratan R.R. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front. Biosci. 2008, 13:2875-2887.
57. Teng X., Sakai T., Liu L., Sakai R., Kaji R., Fukui K. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway. J. Neurochem. 2006, 97:1126-1135.
58. Wang G., Pan J., Chen S.D. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease. Prog. Neurobiol. 2012, 98:207-221.
59. Weinreb O., Mandel S., Youdim M.B., Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic. Biol. Med. 2013, 62:52-64.
60. Wu Y., Li X., Xie W., Jankovic J., Le W., Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem. Int. 2010, 57:198-205.
61. Xu L., Pathak P.S., Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin. Cancer Res. 2004, 10:701-707.
62. You L.H., Li F., Wang L., Zhao S.E., Wang S.M., Zhang L.L., Zhang L.H., Duan X.L., Yu P., Chang Y.Z. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease. Neuroscience 2015, 284:234-246.
63. Youdim M.B., Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J. Neural Transm. Suppl. 1993, 40:57-67.
64. Youdim M.B., Stephenson G., Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 2004, 1012:306-325.
65. Yu S., Zheng W., Xin N., Chi Z.H., Wang N.Q., Nie Y.X., Feng W.Y., Wang Z.Y. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 2010, 13:55-64.
66. Zecca L., Casella L., Albertini A., Bellei C., Zucca F.A., Engelen M., Zadlo A., Szewczyk G., Zareba M., Sarna T. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 2008, 106:1866-1875.
67. Zhang H., Wu F., Kong X., Yang J., Chen H., Deng L., Cheng Y., Ye L., Zhu S., Zhang X., Wang Z., Shi H., Fu X., Li X., Xu H., Lin L., Xiao J. Nerve growth factor improves functional recovery by inhibiting endoplasmic reticulum stress-induced neuronal apoptosis in rats with spinal cord injury. J. Transl. Med. 2014, 12:130.
68. Zhang S., Wang J., Song N., Xie J., Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 2009, 30:1466-1476.
69. Zhang Z., Zhang K., Du X., Li Y. Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration. Mol. Med. Rep. 2012, 5:562-566.
70. Zhu W., Li X., Xie W., Luo F., Kaur D., Andersen J.K., Jankovic J., Le W. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol. Dis. 2010, 37:307-313.